Table 1.
Cataract
|
Glaucoma
|
|||||||
---|---|---|---|---|---|---|---|---|
Cases (N = 2404) | Controls (N = 5621) | Cases (N = 273) | Controls (N = 703) | |||||
N | (%) | N | (%) | N | (%) | N | (%) | |
Age at indexa | ||||||||
45–49 | 0 | 0 | 2 | (0.04) | – | – | – | – |
50–54 | 8 | (0.3) | 22 | (0.4) | 3 | (1.1) | 8 | (1.1) |
55–59 | 54 | (2.3) | 129 | (2.3) | 9 | (3.3) | 20 | (2.8) |
60–64 | 122 | (5.1) | 329 | (5.9) | 24 | (8.8) | 54 | (7.7) |
65–69 | 284 | (11.8) | 781 | (13.9) | 44 | (16.1) | 126 | (17.9) |
70–74 | 472 | (19.6) | 1220 | (21.7) | 61 | (22.3) | 159 | (22.6) |
75–79 | 697 | (29) | 1674 | (29.8) | 66 | (24.2) | 179 | (25.5) |
80–85 | 653 | (27.2) | 1274 | (22.7) | 54 | (19.8) | 138 | (19.6) |
≥86 | 114 | (4.7) | 190 | (3.4) | 12 | (4.4) | 19 | (2.7) |
Gender | ||||||||
Female | 1235 | (51.4) | 2793 | (49.7) | 143 | (52.4) | 357 | (50.8) |
Male | 1169 | (48.6) | 2828 | (50.3) | 130 | (47.6) | 346 | (49.2) |
BMI | ||||||||
Missing | 1203 | (50.0) | 2958 | (52.6) | 138 | (50.6) | 366 | (52.1) |
10–18.49 | 82 | (3.4) | 185 | (3.3) | 4 | (1.5) | 23 | (3.3) |
18.50–24.99 | 435 | (18.1) | 963 | (17.1) | 56 | (20.5) | 111 | (15.7) |
25–29.99 | 382 | (15.9) | 881 | (15.7) | 39 | (14.3) | 109 | (15.5) |
30–70 | 302 | (12.6) | 634 | (11.3) | 36 | (13.2) | 94 | (13.4) |
Smoking status | ||||||||
Nonsmoker | 348 | (14.5) | 743 | (13.2) | 31 | (11.4) | 91 | (12.9) |
Ex-smoker | 1112 | (46.3) | 2437 | (43.4) | 120 | (44) | 292 | (41.5) |
Smoker | 493 | (20.5) | 1324 | (23.6) | 69 | (25.3) | 186 | (26.5) |
Unknown | 451 | (18.8) | 1117 | (19.9) | 53 | (19.4) | 134 | (19.1) |
Comorbid conditions | ||||||||
Vertebral fracture | 11 | (0.5) | 24 | (0.4) | 2 | (0.7) | 3 | (0.4) |
Depression | 120 | (5) | 228 | (4.1) | 12 | (4.4) | 38 | (5.4) |
Diabetes | 350 | (14.6) | 538 | (9.6) | 23 | (8.4) | 76 | (10.8) |
Rheumatoid arthritis | 11 | (0.5) | 40 | (0.7) | 0 | 0 | 5 | (0.7) |
Asthma | 276 | (11.5) | 625 | (11.1) | 35 | (12.8) | 75 | (10.7) |
Osteoporosis | 53 | (2.2) | 112 | (1.2) | 7 | (2.6) | 11 | (1.6) |
Stroke | 38 | (1.6) | 74 | (1.3) | 4 | (1.5) | 10 | (1.4) |
Anemia | 90 | (3.7) | 184 | (3.3) | 5 | (1.8) | 20 | (2.8) |
Osteopenia | 13 | (0.5) | 26 | (0.5) | 1 | (0.4) | 5 | (0.7) |
Back pain | 307 | (12.8) | 627 | (11.2) | 40 | (14.7) | 86 | (12.2) |
Falls | 137 | (5.7) | 247 | (4.4) | 14 | (5.1) | 31 | (4.4) |
Hyperparathyroid | 4 | (0.2) | 4 | (0.1) | 0 | 0 | 1 | (0.14) |
Dementia | 9 | (0.4) | 28 | (0.5) | 2 | (0.7) | 7 | (1.0) |
Hypertension | 364 | (15.1) | 946 | (16.8) | 47 | (17.2) | 115 | (16.4) |
Dyslipidemia | 114 | (4.7) | 243 | (4.3) | 15 | (5.5) | 20 | (2.84) |
Obesity | 306 | (12.7) | 639 | (11.4) | 36 | (13.2) | 95 | (13.5) |
Antibiotic: number of scripts in the previous year | ||||||||
None | 723 | (30.1) | 1907 | (34) | 83 | (30.4) | 245 | (34.9) |
1 | 440 | (18.3) | 1257 | (22.4) | 63 | (23.1) | 154 | (21.9) |
2 | 344 | (114.3) | 832 | (14.8) | 37 | (13.6) | 100 | (14.2) |
3–4 | 434 | (18.1) | 876 | (15.6) | 41 | (15.0) | 125 | (17.8) |
≥5 | 463 | (19.3) | 749 | (13.3) | 49 | (18) | 79 | (11.2) |
Number of COPD visits | ||||||||
None | 549 | (22.9) | 1366 | (24.3) | 75 | (27.5) | 185 | (26.3) |
1 | 990 | (41.2) | 2385 | (42.4) | 104 | (38.1) | 277 | (39.4) |
2 | 386 | (16.1) | 968 | (17.2) | 47 | (17.2) | 113 | (16.1) |
3+ | 479 | (19.9) | 902 | (16.1) | 47 | (17.2) | 128 | (18.2) |
Number of COPD hospitalizations | ||||||||
None | 2189 | (91.1) | 5306 | (94.4) | 254 | (93.0) | 662 | (94.2) |
1 | 167 | (7) | 252 | (4.5) | 15 | (5.5) | 33 | (4.7) |
2+ | 48 | (2.0) | 63 | (1.1) | 4 | (1.5) | 8 | (1.1) |
Comedications | ||||||||
FSC | 799 | (33.2) | 1655 | (29.4) | 78 | (28.6) | 226 | (32.2) |
ICS-containing product | 1823 | (75.8) | 3961 | (70.5) | 197 | (72.2) | 510 | (72.6) |
BDP-containing product | 847 | (35.2) | 1990 | (35.4) | 90 | (33) | 223 | (31.7) |
BUD-containing product | 350 | (14.6) | 663 | (11.8) | 43 | (15.8) | 95 | (13.5) |
FP-containing product | 898 | (37.4) | 1864 | (33.2) | 88 | (32.2) | 253 | (36) |
Oral corticosteroids | 1098 | (45.7) | 2128 | (37.9) | 119 | (43.6) | 264 | (37.6) |
Antibiotic | 1681 | (69.9) | 3714 | (66.1) | 190 | (69.6) | 458 | (65.2) |
Statin | 850 | (35.4) | 1763 | (31.4) | 76 | (27.8) | 210 | (29.9) |
Nebulizer | 476 | (19.8) | 761 | (13.5) | 51 | (18.7) | 92 | (13.1) |
Other respiratory product | 1369 | (56.9) | 2827 | (50.3) | 146 | (53.5) | 359 | (51.1) |
Oxygen | 160 | (6.7) | 268 | (4.8) | 15 | (5.5) | 45 | (6.4) |
Tiotropium-only product | 616 | (25.6) | 1224 | (21.8) | 57 | (20.9) | 164 | (23.3) |
SABD-containing product | 2156 | (89.7) | 4898 | (87.1) | 229 | (83.9) | 603 | (85.8) |
SABD with ICS product | 0 | 0 | 3 | (0.1) | NA | NA | NA | NA |
ICS-containing product excluding FSC | 1260 | (52.4) | 2799 | (49.8) | 136 | (49.8) | 338 | (48.1) |
Notes: Population includes patients with COPD in the GPRD between 2003 and 2006. Controls matched to cases on gender, age within 2 years, general practice, and number of years in the cohort prior to the event of interest.
Index date is the date of the incident case of cataract or glaucoma and matched control.
Abbreviations: BDP, beclomethasone dipropionate; BMI, body mass index; BUD, budesonide; FSC, fluticasone propionate/salmeterol fixed-close combination; FP, fluticasone propionate; GPRD, General Practice Research Data base; SABD, short-acting bronchodilator; NA, not applicable.